Literature DB >> 15464056

Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis.

Shinji Takai1, Denan Jin, Michiko Muramatsu, Yukiko Okamoto, Mizuo Miyazaki.   

Abstract

Chymase activates not only angiotensin I to angiotensin II but also latent transforming growth factor-beta-binding protein to transforming growth factor-beta. In dog grafted veins, chymase activity and angiotensin II concentration along with vascular proliferation were significantly increased, while they were significantly suppressed by a chymase inhibitor. After balloon injury in dog arteries, chymase activity was significantly increased in the injured artery, and a chymase inhibitor and an angiotensin AT(1) receptor antagonist were effective in preventing the vascular proliferation, but an angiotensin-converting enzyme inhibitor was ineffective. In fibrotic models, the tissue fibrosis was reduced by chymase inhibitors. In adhesion models, the transforming growth factor-beta concentration and adhesion formation were suppressed by chymase inhibitors. Therefore, chymase inhibitors may be useful for preventing cardiovascular diseases and fibrosis via inhibition of angiotensin II formation and transforming growth factor-beta activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464056     DOI: 10.1016/j.ejphar.2004.08.040

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia.

Authors:  Jie Chao; Gustavo Blanco; John G Wood; Norberto C Gonzalez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

2.  Reduction of adhesion formation by an angiotensin type 1 receptor antagonist.

Authors:  Yasuyuki Tokinaga; Yoshiki Kimoto; Koji Ogawa; Kazuhiro Mizumoto; Kazuaki Tange; Yoshio Hatano
Journal:  Langenbecks Arch Surg       Date:  2010-07-01       Impact factor: 3.445

Review 3.  Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Jasmina Varagic; Che Ping Cheng; Leanne Groban; Hao Wang; James F Collawn; Louis J Dell Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-27       Impact factor: 4.733

Review 4.  Mast cell proteases as protective and inflammatory mediators.

Authors:  George H Caughey
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 5.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

Review 6.  Histamine receptors in heart failure.

Authors:  Scott P Levick
Journal:  Heart Fail Rev       Date:  2021-10-08       Impact factor: 4.654

7.  Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters.

Authors:  Tao Wang; Su-Xia Han; Shang-Fu Zhang; Yun-Ye Ning; Lei Chen; Ya-Juan Chen; Guang-Ming He; Dan Xu; Jin An; Ting Yang; Xiao-Hong Zhang; Fu-Qiang Wen
Journal:  Respir Res       Date:  2010-03-31

8.  Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease.

Authors:  Djuro Kosanovic; Bhola Kumar Dahal; Dorothea Maren Peters; Michael Seimetz; Malgorzata Wygrecka; Katrin Hoffmann; Jochen Antel; Irwin Reiss; Hossein Ardeschir Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph Theo Schermuly
Journal:  Pulm Circ       Date:  2014-03       Impact factor: 3.017

9.  Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.

Authors:  Vijay Koka; Wansheng Wang; Xiao Ru Huang; Shokei Kim-Mitsuyama; Luan D Truong; Hui Y Lan
Journal:  Circulation       Date:  2006-03-06       Impact factor: 29.690

Review 10.  The possible potential therapeutic targets for drug induced gingival overgrowth.

Authors:  Tamilselvan Subramani; Vidhya Rathnavelu; Noorjahan Banu Alitheen
Journal:  Mediators Inflamm       Date:  2013-04-16       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.